Compare HOMB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOMB | ERAS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 2006 | 2021 |
| Metric | HOMB | ERAS |
|---|---|---|
| Price | $28.00 | $17.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $32.40 | $12.08 |
| AVG Volume (30 Days) | 1.2M | ★ 4.8M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | 19.90 | ★ 36.23 |
| EPS | ★ 2.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.99 | N/A |
| Revenue Next Year | $5.14 | N/A |
| P/E Ratio | $11.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.98 | $1.06 |
| 52 Week High | $30.83 | $18.20 |
| Indicator | HOMB | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 62.62 |
| Support Level | $27.68 | $1.57 |
| Resistance Level | $28.74 | N/A |
| Average True Range (ATR) | 0.51 | 1.03 |
| MACD | 0.27 | 0.07 |
| Stochastic Oscillator | 72.86 | 73.62 |
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.